IP Library › Granted Patent US 11,180,550
Granted Patent B2
US 11,180,550 · App. 16/594,871 · Granted Nov 23, 2021

Compositions and methods for treating cancer

Inventors: Daniel J. Powell (Bala Cynwyd, PA); George Coukos (Wynnewood, PA); Mariangela Figini (Milan, IT); Silvana Canevari (Milan, IT)
Assignees: The Trustees of the University of Pennsylvania; Fondazione IRCCS Istituto Nazionale dei Tumori
C07K16/28A61K35/17A61K39/0011A61K39/39558C07K14/705C07K14/7051C07K14/70517C07K14/70578A61K2035/124A61K2039/505A61K2039/5156A61K2039/5158C07K2317/622C07K2318/20C07K2319/02C07K2319/03C07K2319/30C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,180,550
App. No.
16/594,871
Granted
Nov 23, 2021
Kind
B2
Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Claims (22)

1. A cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the nucleic acid sequence comprises a sequence encoding an α-folate receptor (FRα) antibody comprising the amino acid sequence of SEQ ID NO: 23.

2. The cell of claim 1 , wherein the CAR further comprises a CD3 zeta signaling domain.

3. The cell of claim 2 , wherein the CD3 zeta signaling domain comprises an amino acid sequence of SEQ ID NO: 19.

4. The cell of claim 2 , wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence of SEQ ID NO: 7.

5. The cell of claim 1 , wherein the CAR further comprises a transmembrane domain.

6. A cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an α-folate receptor (FRα) antibody comprising the amino acid sequence of SEQ ID NO: 23.

7. The cell of claim 6 , wherein the CAR further comprises a CD3 zeta signaling domain.

8. The cell of claim 7 , wherein the CD3 zeta signaling domain comprises an amino acid sequence of SEQ ID NO: 19.

9. The cell of claim 7 , wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence of SEQ ID NO: 7.

10. The cell of claim 6 , wherein the CAR further comprises a transmembrane domain.

11. The cell of claim 6 , wherein the CAR further comprises a 4-1BB costimulatory domain.

12. The cell of claim 11 , wherein the 4-1BB costimulatory domain comprises an amino acid sequence of SEQ ID NO: 18.

13. The cell of claim 11 , wherein the 4-1BB costimulatory domain is encoded by the nucleic acid sequence of SEQ ID NO: 6.

14. The cell of claim 1 , wherein the CAR further comprises a 4-1BB costimulatory domain.

15. The cell of claim 14 , wherein the 4-1BB costimulatory domain comprises an amino acid sequence of SEQ ID NO: 18.

16. The cell of claim 14 , wherein the 4-1BB costimulatory domain is encoded by the nucleic acid sequence of SEQ ID NO: 6.

17. The cell of claim 1 , wherein the cell is a mammalian cell.

18. The cell of claim 6 , wherein the cell is a mammalian cell.

19. The cell of claim 1 , wherein the cell is an immune cell.

20. The cell of claim 6 , wherein the cell is an immune cell.

21. The cell of claim 19 , wherein the immune cell is a T cell.

22. The cell of claim 20 , wherein the immune cell is a T cell.

Continuity (4)
Continuation 15212916 · Jul 18, 2016
Continuation 13979927
Provisional Application 61433731 · Jan 18, 2011
Related Publication 20200270341A1 · Aug 27, 2020